Klotho Neurosciences today announced it has signed a nonbinding Letter of Intent to acquire select assets from Turn Biotechnologies, in a transaction anchored by a $300 million global pharma deal, according to the company.
Under the proposed deal, Klotho would obtain Turn’s ERA (Epigenetic Reprogramming of Age) platform and the eTurna RNA delivery system. The company said that these technologies aim to rejuvenate somatic cells and restore tissue function across multiple therapeutic areas including dermatology, ophthalmology, immunology, osteoarthritis, muscle health, and diseases such as ALS.
As part of the agreement, Klotho would also assume a signed out-licensing and co-development partnership with a leading South Korean pharmaceutical firm valued at up to $300 million. The company claims this partnership demonstrates commercial interest in Turn’s platform and underscores its broad therapeutic potential.
The transaction is subject to due diligence, definitive agreements, and customary closing conditions. Upon closing, Klotho plans to rebrand to reflect its expanded therapeutic focus and intends to integrate key members of Turn’s management and R&D teams.
Klotho said that the move is intended to expand its mission from a single gene approach (the Klotho gene) into a broader system of cellular rejuvenation. The company envisions applying the combined technologies to diseases of aging, including neurological, musculoskeletal, and ophthalmic disorders.
If completed, Klotho claims the acquisition would strengthen its position in the longevity medicine field and expand its therapeutic reach.
